COR2ED brings you Independent Medical Education developed by NET CONNECT, international experts in neuroendocrine tumours.https://xitter.cf/t.co/X1u06YqRt7
Joined October 2018
- Tweets760
- Following556
- Followers1.5K
- Likes445
Pinned Tweet
📺 Highlights from #ENETS2026
Discover the latest clinical practice changing insights from the conference in Krakow, Poland.
Experts Prof. Louis de Mestier, Prof. @TimonV and Dr Alice Durand share insights into new data on PRRT in treatment sequencing and re-challenge in NETs, obrixtamig as 1st line therapy in advanced NEC, and the role of surgery in stage 1–3 disease. In addition, they discuss interesting combination treatment.
How will new data impact clinical practice? Watch the video below to find out.
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
#MedEd #NeuroendocrineTumors #NeuroendocrineCancer #NETs #NETCancer
NET CONNECT powered by COR2ED retweeted
Check out our Collaborators at COR2ED and this EXPERT insights from #ESMO26
GI oncologists Dr Lizzy Smyth, Dr Yelena Janjigian and Assoc. Prof. Gerald Prager join COR2ED at ESMO 2026 to provide their instant reactions on new data presented at the meeting. While Drs Smyth and Janjigian discuss gastric/GEJ cancer developments, Dr Prager will be focusing on colorectal and pancreatic cancer. @LizzySmyth1, @YJanjigianMD
cor2ed.com/esmo-2026/gastric…
NET CONNECT powered by COR2ED retweeted
🎙️ ESMO 2026: Expert insights in NSCLC
Our Collaborators at @COR2EDMedEd met with medical oncologist Dr Louise Lim at ESMO 2026 , to discuss the latest non-small cell lung cancer (NSCLC) data and what it could mean for clinical practice. 👉 cor2ed.com/highlights-from-e…
🔬 Key studies in focus:
▪️ KRAS G12C: KRAScendo 1 (LBA5)
▪️ EGFR-mutated, MET-driven NSCLC: SAFFRON (LBA6)
▪️ First-line PD-L1-negative NSCLC: OptiTROP-Lung06 (LBA66)
▪️ EGFR-mutated NSCLC post-TKI: OptiTROP-Lung04 (LBA67)
Join us for expert perspectives on these emerging data and their potential implications for treatment decisions.📍 Recorded at ESMO 2026
#ESMO26 #LungCancer
NET CONNECT powered by COR2ED retweeted
🎥 #ESMO26 highlights from our collaborators @COR2EDMedEd Visit them at the main exhibition hall to learn more
Watch Here👉 buff.ly/HBEGYqU
Leading experts give quick takes on the key data, ~3 min per tumour type:
🔹 Gastric/GEJ: Smyth & Janjigian
🔹 CRC & pancreatic: Prager
🔹 HCC: Chon & Rimassa
🔹 NSCLC: Newsom-Davis & Lim
🔹 Breast: Jhaveri
🔹 GU: Iacovelli
@YJanjigianMD, @tnewsomdavis, @LorenzaRimassa, @jhaveri_komal, @DrIacovelli @COR2EDMedEd
NET CONNECT powered by COR2ED retweeted
Drs @jhaveri_komal and @DrIacovelli are joining our collaborators at COR2ED at ESMO 2026 to share their thoughts on the latest data presented at the meeting. Dr Jhaveri will provide insights on #BreastCancer 🇺🇸 data, while Dr Iacovelli 🇮🇹 will review developments in #ProstateCancer and #BladderCancer
👉 Explore the coverage cor2ed.com/highlights-from-e…
NET CONNECT powered by COR2ED retweeted
📣 Come and see us in Madrid at #ESMO26!
📍 Hall 10, Booth 1031
Get your FREE headshot from our professional photographer, and browse our library of high-quality #MedicalEducation programmes
🩺 We work with renowned medical experts to translate the latest science into #clinicalpractice
🧬 Our content spans a wide range of therapy areas
🎙️Formats include podcasts, videos, micro learnings, patient cases, and more
✅ Most of our programmes are endorsed by medical societies and patient advocacy groups
See you there!
#Oncology #OncTwitter #OncologyNursing #MedTwitter #MedEd @myESMO
Dernières données de l’ENETS 2026
Quel sera l’impact des nouvelles données sur la pratique clinique?
Analyses d’experts du Pr Louis de Mestier, du Pr Timon Vandamme et du Dr Alice Durand
📺 Regardez les dernières actualités sur:
-Résultats marquants de l’étude COMPETE avec la RIV dans les TNE pancréatiques avant traitement ciblés
-Leurs avis sur les stratégies de retraitement (re-challenge) par RIV
-Les données positives de l’essai DAREONᵀᴹ-7 sur l’obrixtamig, un engageur bispécifique des lymphocytes T ciblant DLL3, en traitement de 1re ligne du CNE avancé
-Le rôle de la chirurgie dans les maladies de stade 1–3
-L’intéressante association thérapeutique du cabozantinib et du témozolomide pour les TNE
Ce programme éducatif bénéficie d’une subvention éducative indépendante d’Ipsen. Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale
Experts review data presented at ENETS 2026
From Prof. Louis de Mestier, Prof. Timon Vandamme (@TimonV), & Dr Alice Durand 📺
They discuss:
>> Breakthrough results from the COMPETE study with PRRT in pancreatic NETS before targeted therapy
>> Strategies for re-challenge with PRRT
>> Positive data from the DAREONᵀᴹ-7 trial of obrixtamig, a DLL3-targeted bi-specific T cell engager, as 1st line therapy for advanced NEC
>> The role of surgery in stage 1–3 disease
>> The interesting combination treatment of cabozantinib and temozolomide for NETs
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
Missed the latest data from #ENETS26?
Catch up with expert insights on new and emerging treatment strategies across neuroendocrine tumours, including PRRT, DLL3-targeted therapy, and surgery.
Hear from Prof’s Louis de Mestier and Timon Vandamme, and Dr Alice Durand.
#MedEd
Experts review data presented at ENETS 2026
From Prof. Louis de Mestier, Prof. Timon Vandamme (@TimonV), & Dr Alice Durand 📺
They discuss:
>> Breakthrough results from the COMPETE study with #PRRT in pancreatic #NETS before targeted therapy
>> Strategies for re-challenge with PRRT
>> Positive data from the DAREONᵀᴹ-7 trial of obrixtamig, a DLL3-targeted bi-specific T cell engager, as 1st line therapy for advanced NEC
>> The role of surgery in stage 1–3 disease
>> The interesting combination treatment of cabozantinib and temozolomide for NETs
See more & get the clinical takeaways: cor2ed.com/net-connect/progr…
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
#MedEd #OncTwitter #NETs
#NeuroendocrineTumors #NeuroendocrineCancer #NETCancer
Experts review data presented at ENETS 2026
From Prof. Louis de Mestier, Prof. Timon Vandamme (@TimonV), & Dr Alice Durand 📺
They discuss:
>> Breakthrough results from the COMPETE study with #PRRT in pancreatic #NETS before targeted therapy
>> Strategies for re-challenge with PRRT
>> Positive data from the DAREONᵀᴹ-7 trial of obrixtamig, a DLL3-targeted bi-specific T cell engager, as 1st line therapy for advanced NEC
>> The role of surgery in stage 1–3 disease
>> The interesting combination treatment of cabozantinib and temozolomide for NETs
See more & get the clinical takeaways: cor2ed.com/net-connect/progr…
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
#MedEd #OncTwitter #NETs
#NeuroendocrineTumors #NeuroendocrineCancer #NETCancer
Revue d’experts des données présentées à l’ENETS 2026
Avec le Pr Louis de Mestier, le Pr Timon Vandamme (@TimonV) et le Dr Alice Durand 📺
Ils échangent sur :
>> Résultats marquants de l’étude COMPETE avec la RIV dans les TNE pancréatiques avant traitement ciblés
>> Leurs avis sur les stratégies de retraitement (re-challenge) par RIV
>> Les données positives de l’essai DAREONᵀᴹ-7 sur l’obrixtamig, un engageur bispécifique des lymphocytes T ciblant DLL3, en traitement de 1re ligne du CNE avancé
>> Le rôle de la chirurgie dans les maladies de stade 1–3
>> L’intéressante association thérapeutique du cabozantinib et du témozolomide pour les TNE
Voir plus et découvrir les principaux enseignements cliniques : cor2ed.com/net-connect/progr…
Ce programme éducatif bénéficie d’une subvention éducative indépendante d’Ipsen. Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale
#MedEd #OncTwitter #NETs
#TumeursNeuroendocrines #CancerNET
The latest data from ENETS 2026
How will new data impact clinical practice? 📈
Expert insights from Prof. Louis de Mestier, Prof. Timon Vandamme (@TimonV), & Dr Alice Durand
📺 Watch for an update on:
-Breakthrough results from the COMPETE study with #PRRT in pancreatic #NETS before targeted therapy
-Strategies for re-challenge with PRRT
-Positive data from the DAREONᵀᴹ-7 trial of obrixtamig, a DLL3-targeted bi-specific T cell engager, as 1st line therapy for advanced NEC
-The role of surgery in stage 1–3 disease
-The interesting combination treatment of cabozantinib and temozolomide for NETs
Get the key clinical takeaways: cor2ed.com/net-connect/progr…
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
#MedEd #OncTwitter #NETs
#NeuroendocrineTumors #NeuroendocrineCancer #NETCancer #ENETS2026
The latest data in #NeuroendocrineCancer: expert insights from #ENETS2026
📺 From Prof. Louis de Mestier Prof. Timon Vandamme (@TimonV), & Dr Alice Durand
See more: cor2ed.com/net-connect/progr…
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
#MedEd #OncTwitter #NETs
#NeuroendocrineTumors #NeuroendocrineCancer #NETCancer
NET CONNECT powered by COR2ED retweeted
🧬 Which ENETS 2026 updates should NET specialists be watching most closely? @COR2EDMedEd @net_connectinfo
Drs. Louis de Mestier, Timon Vandamme (@TimonV), and Alice Durand review new data on PRRT, DLL3-targeted therapy, surgery in NEC, and emerging combination strategies.
🎥 Watch on #Vumedi: tinyurl.com/y94xtaaf
#NeuroendocrineTumors #PRRT
NET CONNECT powered by COR2ED retweeted
📹 Discover the latest clinical practice changing insights from the ENETS 2026 conference in Krakow, Poland.
Prof. Louis de Mestier, Prof. Timon Vandamme, and Dr Alice Durand share insights into new data on PRRT in treatment sequencing and re-challenge in NETs, obrixtamig as 1st line therapy in advanced NEC, and the role of surgery in stage 1–3 disease. In addition, they discuss interesting combination treatment.
How will new data impact clinical practice? Watch to find out.
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
Update from #ENETS2026 📺
Get key takeaways from the congress, including:
🔎 Results of the COMPETE trial subgroup analysis comparing PRRT and everolimus
🔎 What the latest data from the DAREONᵀᴹ-7 trial reveal about obrixtamig, a DLL3 bi-specific T cell engager
🔎 The role of surgical resection in stage 1–3 NECs
🔎Strategies for re-challenging PRRT in NET patients
🔎 The interesting combination treatment of cabozantinib and temozolomide for NETs
From Prof. Louis de Mestier, Prof. Timon Vandamme (@TimonV), & Dr Alice Durand
See more! >> cor2ed.com/net-connect/progr…
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
#MedEd #OncTwitter #NETs
#NeuroendocrineTumors #NeuroendocrineCancer #NETCancer
NET CONNECT powered by COR2ED retweeted
The latest data from ENETS 2026
How will new data impact clinical practice? 📈
Expert insights from Prof. Louis de Mestier, Prof. Timon Vandamme (@TimonV), & Dr Alice Durand
📺 Watch for an update on:
-Breakthrough results from the COMPETE study with #PRRT in pancreatic #NETS before targeted therapy
-Strategies for re-challenge with PRRT
-Positive data from the DAREONᵀᴹ-7 trial of obrixtamig, a DLL3-targeted bi-specific T cell engager, as 1st line therapy for advanced NEC
-The role of surgery in stage 1–3 disease
-The interesting combination treatment of cabozantinib and temozolomide for NETs
Get the key clinical takeaways: cor2ed.com/net-connect/progr…
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
#MedEd #OncTwitter #NETs
#NeuroendocrineTumors #NeuroendocrineCancer #NETCancer #ENETS2026
NET CONNECT powered by COR2ED retweeted
📢Hepatopancreaticobiliary-NET abstracts in #ESMO24 @myESMO
➡️HCC
✅LBA3 - Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study
✅LBA38 - Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): a randomized, open-label, phase 2/3 study (DUBHE-H-308)
✅LBA39 - Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
✅LBA40 - Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
✅965MO - Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): expanded analyses from CheckMate 9DW
✅947MO - Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
➡️Pancreatic
✅LBA62 - Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II trial PANDAS/PRODIGE 44
✅LBA63 - A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy
✅1504MO - Phase 2 Trial of Pembrolizumab and OLApaRib (POLAR) Maintenance for Select Patients (pts) with Metastatic Pancreatic Cancer (mPC) with (A) Homologous Recombination Deficiency (HRD), (B) non-core HRD (ncHRD) and (C) Exceptional Response to Platinum
✅LBA63 - A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy
✅1504MO - Phase 2 Trial of Pembrolizumab and OLApaRib (POLAR) Maintenance for Select Patients (pts) with Metastatic Pancreatic Cancer (mPC) with (A) Homologous Recombination Deficiency (HRD), (B) non-core HRD (ncHRD) and (C) Exceptional Response to Platinum
✅1O - The somatic mutation landscape of the normal and malignant pancreas
➡️Biliary
-
➡️NETs
✅1145MO - CVM-005: Phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in advanced neuroendocrine tumors (NET) after progression on prior therapy
✅1146MO - Interim analysis of CABONEN – a multicenter phase II trial investigating Cabozantinib in patients with advanced, low proliferative NEN G3
✅1147MO - Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): An AIO phase II multicenter single-arm study
✅1148MO - A Multivariate Efficacy Analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 Study
✅1149MO - Carcinoid Heart Disease in Patients with Advanced Small-intestinal Neuroendocrine Tumours and Carcinoid Syndrome: A Retrospective experience of two Centers of Excellence
✅1141O - Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) after Progression on Prior Therapy (CABINET Trial/Alliance A021602): Updated Results Including Progression Free-Survival (PFS) by Blinded Independent Central Review (BICR) and Subgroup Analyses
✅1142O - Multivariable Analysis of Streptozotocin plus 5-Fluorouracil and Everolimus Sequences in Advanced Pancreatic Neuroendocrine Tumor patients: The SEQTOR Trial (GETNE-1206)
✅1143O - Refining molecular classification of neuroendocrine tumors from diverse origins using multi-omic integration models. Unveiling novel neuroendocrine subtypes and their clinical implications
✅1144O - Osteopontin (OPN) predicts the efficacy of anti-angiogenic therapy with multikinase inhibitors (MKIs) in advanced neuroendocrine tumors (NETs): underlying molecular mechanisms.
@OncoAlert @Annals_Oncology @ESMO_Open #cancer #Oncology #MedX
NET CONNECT powered by COR2ED retweeted
EP-NEC = distinct, aggressive subtype of #neuroendocrine cancer
Often has late diagnosis, frequent mis-categorisation, and mis-understanding
Complexity & burden of EP-NEC increased by delays in diagnosis/pt confusion/inconsistent Tx pathways/limited specialist access
How can pts thrive after EP-NEC diagnosis?
📺 Watch the video to find out
From Jessica Thomas, Director of Patient Education at the Neuroendocrine Tumor Research Foundation
🤝 Endorsed by @CureNETs & Minkahz NETs Mission
See more of this programme: cor2ed.com/net-connect/progr…
Supported by an Independent Educational Grant from Boehringer Ingelheim
#MedEd #OncTwitter #neuroendocrine
📣 Update from #ENETS2026
Experts share their views on the latest practice-changing data in #neuroendocrinecancer
📺 From Prof. Louis de Mestier, Prof. Timon Vandamme (@TimonV), & Dr Alice Durand
The experts discuss:
➡️ Breakthrough results presented from the COMPETE study
➡️ Positive data from the DAREONᵀᴹ-7 trial
➡️ The interesting combination treatment of cabozantinib and temozolomide for NETs
…and more!
See the rest of this programme & get the key clinical takeaways: cor2ed.com/net-connect/progr…
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
#MedEd #OncTwitter #NETs
#NeuroendocrineTumors #NETCancer
NET CONNECT powered by COR2ED retweeted
Join us live from #ASCO26 as Herbert Loong and Isabel Preeshagul discuss the latest advances in HER2-mutant NSCLC presented at ASCO 2026.
👉 buff.ly/eQiz2b7
In this expert discussion, they review key data and share practical perspectives on:
• SOHO-01 — Updated safety and efficacy of sevabertinib in advanced HER2-mutant NSCLC
• Beamion LUNG-3 — Zongertinib in resectable HER2-mutant NSCLC
• Best practices in HER2 testing — Advancing HER2 testing and evidence-based treatment in NSCLC across academic and community settings
• Beamion LUNG-1 PRO analysis — Patient-reported outcomes in treatment-naïve HER2-mutant advanced NSCLC
Brought to you by our Collaborators at COR2ED
@ipreeshagul @herbloong